CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Novo targets oral macrocycles with $1.4bn Orbis partnership

Partnershiporal macrocyclesPositive
AI Analysis

Summary

Novo Nordisk has entered a $1.4bn partnership with Orbis to develop oral macrocycles, reflecting growing pharmaceutical industry interest in compounds bridging small molecules and biologics.

Importance:7/10
Sentiment:
0.50
partnershipmacrocyclesdrug developmentacquisition
Related Companies

Read the original article

Published by Pharmaceutical Technology on September 18, 2026 10:16 AM

Read Original